XTalks

JANUARY 2, 2024

Filsuvez topical gel is a sterile botanical drug product designed for topical use, containing birch triterpenes within an oil base. For instance, Vyjuvek , the first FDA-approved gene therapy for DEB, is priced at $24,250 per vial. Vyjuvek is a gene therapy that employs a herpes simplex virus type 1 (HSV-1) vector.

FDA Approval 111

FDA Approval Gene Therapy Gene Trials 111

The Pharma Data

NOVEMBER 4, 2020

TSX: CTX) (OTC US: CRRTF) (“Crescita” or the “Company”), a growth-oriented, innovation-driven Canadian commercial dermatology company with in-house research & development (“R&D”) and manufacturing capabilities, today announced that it has entered into an exclusive agreement with Juyou-Biotechnology Co.

Licensing 40

Licensing Licensing Dermatology Production 40

The Pharma Data

JANUARY 13, 2021

(IPIX) is a clinical stage biopharmaceutical company developing a world-class portfolio of innovative therapies addressing multiple areas of unmet medical need, including inflammatory diseases, cancer, infectious diseases, and dermatologic diseases. More information is available on the Company website at www.IPharmInc.com.

Clinical Trials 52

Clinical Trials Clinical Trials Trials In-Vitro 52

The Pharma Data

AUGUST 11, 2020

In the field of immune cell therapy, this includes registrational CAR T cell agents for numerous diseases, and a growing early-stage pipeline that expands cell and gene therapy targets, and technologies. Immune-Mediated Skin and Dermatologic Adverse Reactions. Administer corticosteroids for Grade 3 or 4 rash.

Trials 52

Trials Hormones Clinical Trials Clinical Trials 52

The Pharma Data

AUGUST 11, 2020

In the field of immune cell therapy, this includes registrational CAR T cell agents for numerous diseases, and a growing early-stage pipeline that expands cell and gene therapy targets, and technologies. Immune-Mediated Skin and Dermatologic Adverse Reactions. Administer corticosteroids for Grade 3 or 4 rash.

Trials 52

Trials Hormones Clinical Trials Clinical Trials 52

The Pharma Data

SEPTEMBER 15, 2020

Pfizer’s Rare Disease late-stage pipeline currently includes three gene therapy programs that, if successful, are expected to gain regulatory approval by the end of 2023, with an additional pipeline of 10 preclinical initiatives that are at various stages of maturity. Inflammation and Immunology.

Vaccine 52

Vaccine Gene Therapy Vaccination Trials 52

XTalks

AUGUST 2, 2023

It contains the antiviral medications nirmatrelvir and ritonavir. Meanwhile, BioMarin’s gene therapy Roctavian is approved by the FDA for the treatment of hemophilia A. It also has a significant presence in consumer health sectors such as dermatology, nutritionals and allergy. Pfizer’s total global revenue from Paxlovid was $18.93

Sales 98

Sales Manufacturing FDA Approval Life Science 98